EPRX
NASDAQ · Biotechnology
Eupraxia Pharmaceuticals Inc
$7.08
+0.19 (+2.76%)
Financial Highlights (FY 2025)
Revenue
121.08M
Net Income
-20,292,332
Gross Margin
48.2%
Profit Margin
-16.8%
Rev Growth
+21.7%
D/E Ratio
0.16
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 48.2% | 48.2% | 48.2% |
| Operating Margin | -19.3% | -18.0% | -18.9% |
| Profit Margin | -16.8% | -15.7% | -13.2% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 121.08M | 121.80M | 129.11M |
| Gross Profit | 58.40M | 58.75M | 62.27M |
| Operating Income | -23,363,864 | -21,950,536 | -24,418,288 |
| Net Income | -20,292,332 | -19,070,968 | -17,081,441 |
| Gross Margin | 48.2% | 48.2% | 48.2% |
| Operating Margin | -19.3% | -18.0% | -18.9% |
| Profit Margin | -16.8% | -15.7% | -13.2% |
| Rev Growth | +21.7% | +19.1% | -8.5% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 61.96M | 66.90M | 72.48M |
| Total Equity | 382.98M | 378.70M | 384.55M |
| D/E Ratio | 0.16 | 0.18 | 0.19 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -26,386,283 | -29,891,368 | -27,935,877 |
| Free Cash Flow | -23,062,869 | -20,449,670 | -23,278,243 |